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What was the TRUFFLE study?
The Trial of Randomized Umbilical and Fetal Flow
in Europe (TRUFFLE) was a prospective, multicenter,
unblinded, randomized trial that ran between 1 January
2005 and 1 October 2010 in 20 European centers1. It
studied singleton pregnancies at 26–32weeks of gesta-
tion with a diagnosis of fetal growth restriction (FGR),
defined as abdominal circumference< 10th percentile and
high umbilical artery Doppler pulsatility index (PI) (> 95th
percentile). In order to assess whether changes in the fetal
ductus venosus (DV) Doppler waveform or short-term
variation (STV) on cardiotocography (CTG) should be
used as a trigger for delivery in these pregnancies, the 503
included women were randomly allocated to one of three
‘timing-of-delivery’ plans (with 1 : 1 : 1 randomization).
What were the three timing-of-delivery arms?
Women were randomized to one of three groups that
mandated delivery based on either:
(1) reduced STV (‘CTG-STV’ group): abnormal CTG,
defined as fetal heart rate STV< 3.5ms between
#The TRUFFLE Group collaborating authors are listed at the end of the article.
26+ 0 and 28+ 6weeks of gestation or STV< 4ms
between 29+0 and 31+ 6weeks’ gestation; in this
group, DV measurements were not obtained;
(2) early changes in DV waveform (‘DV-p95’ or
‘early-DV’ group): DV-PI > 95th percentile; or
CTG-STV below a ‘safety-net’ level (see box);
(3) late changes in DVwaveform (‘DV-no-A’ or ‘late-DV’
group): DV A-wave (the deflection within the venous
waveform signifying atrial contraction) at or below
the baseline, i.e. indicating no or reversed flow; or
CTG-STV below the same safety net as that for the
DV-p95 group (see box).
What was the ‘safety net’?
The safety net (see box) reflected fetal monitoring para-
meters, agreed by consensus amongst TRUFFLE investi-
gators, that mandated delivery irrespective of randomized
group. This safety net applied to all patients; hence, if the
results of this trial are implemented in guidelines or local
protocols, the safety-net criteria should be an integral
part. In addition, delivery could be indicated in any group
based on maternal conditions (chiefly, pre-eclampsia).
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Safety-net criteria for triggering delivery regardless of
randomized group
STV criteria
Absolute indications for delivery in all randomized arms:
Cut-off ‘rescue’ value for delivery based on
CTG at 26+0 to 28+6weeks is STV<2.6ms
Cut-off ‘rescue’ value for delivery based on
CTG at 29+0 to 31+6weeks is STV<3ms
Delivery is triggered irrespective of STV if there are
spontaneous repeated persistent unprovoked
decelerations on CTG.
Umbilical artery Doppler criteria
Absolute indications for delivery in all randomized arms:
≥32+0weeks: deliver if umbilical artery end-
diastolic flow is reversed
≥34+0weeks: deliver if umbilical artery end-
diastolic flow is absent
Delivery may be undertaken according to local
policies after 30+0weeks if there is reversed
umbilical artery end-diastolic flow, and after
32+0weeks if there is absent umbilical artery
end-diastolic flow.
What were the results for the primary outcome of the
randomized trial?
The primary outcome was survival without cerebral
palsy or neurosensory impairment, or with a Bayley-III
developmental score<85, at 2 years of age.
There are two ways in which to evaluate the primary
outcome. One is to assess ‘survival without neurological
impairment’; in this composite outcome, death is, in
a sense, equivalent to neurological impairment. There
was no significant difference in this outcome among all
pregnancies randomized. However, because neurological
assessment is only possible in surviving infants, the
protocol specified a second way to evaluate the outcome,
in which the primary analysis is restricted to the surviving
infants. This is also justifiable on the grounds that it
is an outcome important to parents. In this analysis,
there were statistically significantly more neurologically
intact 2-year-old babies in the group randomized to
late DV changes (or due to the CTG-STV safety
net) compared with those randomized to CTG: the
proportion without neurodevelopmental impairment at
2 years was 85% in the CTG-STV group, 91% in
the early-DV group and 95% in the late-DV group.
This improvement in neurodevelopmental outcome was
accompanied by a non-significant increase in perinatal and
infant mortality. Both analyses were included in the main
trial report1.
What were the other findings of the TRUFFLE study?
The median gestational age at delivery was 30.7
(interquartile range (IQR), 29.1–32.1) weeks and the
mean birth weight was 1019 (SD, 322) g, confirming
the severe early-onset FGR in the women taking part.
Despite this severity, outcomes were better than those
often reported: over 80% of babies survived and had no
demonstrable neurological impairment at 2 years of age;
12 (2%) fetuses died in utero despite close monitoring;
and 27 (6%) neonatal deaths occurred. The cerebral palsy
rate was around 1%, much lower than that frequently
quoted. Nearly three-quarters of women developed
gestational hypertension. The interval from inclusion to
delivery varied widely (median, 8; IQR, 3–17 days). The
interval was significantly shorter in women who had
pre-eclampsia at inclusion (median, 4; IQR, 2–10 days)
than in those who did not (median, 12; IQR, 5–20 days).
Other parameters, such as allocation group, gestational
age, estimated fetal weight and umbilical artery Doppler
findings, did not affect this interval significantly.
Figure 1 shows the proportion of babies which survived
with no impairment or with impairment and those
which died, both overall and according to gestational
age at recruitment at 26+0 to 28+ 6 and 29+ 0 to
31+ 6weeks2.
Were TRUFFLE babies a highly selected sample?
Early-onset FGR is not common, so in that sense, yes.
However, after excluding fetuses affected by congenital
abnormalities, chromosomal conditions or infections
(based on a careful ultrasound scan, chromosomal testing
when indicated and a blood infection screen), most
had FGR due to uteroplacental insufficiency. These
investigations are all carried out routinely in European
fetal medicine settings and are applicable to any such
setting. It should be noted that there was a group of
cases with even more severe early FGR which were not
eligible for the study; for example, due to not fulfilling the
inclusion criteria for DV-PI or STV. Consequently, the
conclusions of the study should be applied with caution in
such fetuses.
Are the TRUFFLE results generalizable?
The results are generalizable in settings in which
there are specialist fetal medicine experts with the
ability to undertake arterial and venous Doppler
assessments regularly, in which computerized CTG
(cCTG) is available and in which there are high-level
neonatal facilities.
Why was the prevalence of adverse outcomes in
TRUFFLE lower than anticipated?
The better-than-expected outcomes probably reflect the
benefit of being in a trial and being looked after closely by
expert obstetric teams and having expert neonatal care.
These outcomes suggest that clinical care in early-onset
FGR should be undertaken in tertiary-level units. It has
been shown in many studies that joining trials is of
benefit (even in those in which an intervention proves
ineffective)3.
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Figure 1 Proportion of babies with known outcome at 2 years in each of the three randomization groups which survived with no impairment
( ), which survived with impairment ( ) and which died ( ): (a) overall and (b,c) according to gestational age at recruitment, at 26+ 0 to
28+6weeks (b) or at 29+0 to 31+ 6weeks (c). Groups were randomized according to timing of delivery, based on: short-term variation
on cardiotocography (CTG-STV); early changes in ductus venosus (DV) waveform, i.e. DV pulsatility index > 95th percentile (DV-p95); or
late changes in DV waveform, i.e. DV A-wave at or below the baseline (DV-no-A).
Neurological outcome at 2 years of age was better in
the late-DV group. Does this mean I can manage these
pregnancies with Doppler and without cCTG?
No. The timing-of-delivery plan in the group delivered on
late DV changes consisted of a package, which included
cCTG at ‘safety-net’ level alongside DV Doppler. It
should be noted that, in the DV Doppler groups, twice
as many fetuses were delivered on the basis of the
CTG safety-net criteria than were delivered due to DV
changes. Moreover, the somewhat poorer outcome in the
CTG-STV group might be explained by the absence of
a DV safety net in that group, whereas the DV Doppler
groups had a cCTG safety net. One should expect
outcomes similar to those of the TRUFFLE study only by
using DV Doppler and cCTG in conjunction.
My hospital does not use cCTG. Can I use normal
CTG?
We do not recommend this. The CTG monitoring in the
TRUFFLE study was based on computerized assessment
of fetal heart STV. Although there is no randomized
trial evidence against visual interpretation, cCTG is the
only objective measure of fetal heart rate that has been
validated against invasive testing in fetal hypoxemia
and acidemia. Simple visual interpretation of a regular
CTG may not be sufficiently informative or sufficiently
objective to provide reassurance about the fetal condition.
The cCTG equipment used calculated STV based on
the Dawes–Redman algorithm. cCTG will also detect
repetitive fetal heart-rate decelerations, although these
may also be assessed visually. Though we have described
other fetal heart-rate parameters that may be better than
STV for assessing fetal condition in severe FGR4, these
have not yet been evaluated for clinical management.
Given the current interest in the cerebral circulation,
should we deliver based on middle cerebral artery PI,
cerebroplacental ratio or umbilical artery/middle
cerebral artery PI ratio?
No. There were weak associations between middle
cerebral artery (MCA) Doppler and short-term neonatal
outcome, and between MCA Doppler and umbil-
ical:cerebral ratio with 2-year neurodevelopmental
outcome. Although these indices may be informative in
understanding the pathophysiological process, they are
of no proven benefit in the monitoring or management
strategy before 32weeks’ gestation5.
Did neurodevelopmental impairment change with
gestational age and was it related to neonatal
morbidity?
An important strength of the TRUFFLE study is that
babies were followed up to the age of 2 years, allowing
assessment of neurodevelopmental impairment. The over-
all rate was 10%. Although neonatal morbidity was a risk
factor, in most infants with neurodevelopmental impair-
ment this was not preceded by morbidity6 (Figure 2).
But many women in the two DV Doppler groups were
delivered for reasons other than abnormal ductus
venosus Doppler?
Yes – that is true: delivery was undertaken for severe
pre-eclampsia or HELLP syndrome in 54 (11%) women
and for fetal distress not mandated by the study protocol
in a further 55 (11%) women. This was anticipated in the
trial design and does not constitute ‘off-protocol’ delivery.
Such occurrences are a frequent feature of randomized
controlled studies. It is generally recommended to
undertake an ‘intention-to-treat’ analysis; in other words,
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Figure 2 Bar chart showing rates, according to gestational age, of
severe neonatal morbidity ( ) (a composite of one or more of the
following severe morbidities: bronchopulmonary dysplasia, severe
germinal matrix cerebral hemorrhage Grade III or IV, cystic
periventricular leukomalacia, proven neonatal sepsis, necrotizing
enterocolitis) and of neurodevelopmental impairment at 2 years ( )
(a composite of one or more of the following: cognitive Bayley-III
score< 85, disabling cerebral paresis, hearing loss requiring hearing
aid, severe visual loss) in surviving children. There were 31 children
delivered at 26–27weeks, 109 delivered at 28–29weeks, 145
delivered at 30–31weeks, 80 delivered at 32–33weeks and 37
delivered ≥ 34weeks. There was a significant relationship between
neonatal morbidity and gestational age (P < 0.001), but not
between neurodevelopmental impairment and gestational age
(P= 0.40). Adapted from Van Wassenaer-Leemhuis et al.6. 2017
Royal College of Obstericians and Gynaecologists.
analyzing according to the intended delivery criteria rather
than the actual reason for delivery. This is because when
the decision is made to monitor an individual woman
with a certain modality, it is not known which factors
will intercede in the future. Of course, many women
were delivered according to protocol before 32weeks,
and this included those delivered for cCTG safety-net
indication in the early- and late-DV groups. We have
detailed these outcomes7: there was a lower rate of
survival without neurodevelopmental impairment in those
randomized to CTG (which included umbilical artery but
not DV Doppler) than in mothers delivered according
to DV changes. The finding that many women deliver
for reasons other than DV changes means that CTG,
which was an integral part of all three arms, is a key
component of the monitoring strategy and should not be
disregarded.
What about the fact that there were more fetal deaths
in the late-DV group? And why were neurodevelop-
mental outcomes better in survivors within the DV
Doppler groups?
There were 12 fetal deaths in total, two in the CTG-STV
group, four in the early-DV group and six in the late-DV
group; it is likely that the differences in number of
fetal deaths between groups occurred by chance. Fetal
deaths were categorized as unexpected or due to planned
non-intervention. All unexpected deaths occurred in the
DV Doppler groups (three in the early- and four in the
late-DV group). The other five antenatal deaths were
inevitable (parents declined intervention)8. Assessment of
the monitoring parameters that were obtained shortly
before demise in the cases of unexpected fetal death
showed an abnormal CTG in only one. Hence, six of the
seven cases would not have been delivered if they had been
allocated to the CTG-STV group. The pathophysiological
reason why neurodevelopmental outcomes were better in
the DV Doppler groups is not elucidated by the TRUFFLE
study. However, we speculate that both CTG-STV
and DV Doppler are parameters that indicate different
(failing) homeostatic mechanisms. As the sequence of
these changes may vary between fetuses, a combination
of both parameters could be more effective in determining
the moment when the balance of the risks associated
with intervention and with expectant management slides
towards favoring intervention.
What were the findings in fetuses delivered <32weeks?
This was the best defined group of the study since
delivery > 32weeks was undertaken according to local
protocols. Outcomes prior to 32weeks, as for delivery
after 32weeks, were significantly better in those women
randomized to monitoring by DV compared to the
CTG group7,8, with no differences between the two
DV subgroups. Hence, combined DV and CTG (safety
net) monitoring seems to be the best way forward in
managing these cases. So, delivery is indicated if DV
becomes abnormal or if CTG safety-net criteria are met.
In this context, it should not be forgotten that, in the DV
groups, twice as many fetuses were delivered on the basis
of CTG safety-net criteria than on DV abnormalities.
It is also important to bear in mind that CTG safety
net includes the occurrence of spontaneous decelerations
and/or low cCTG-STV values. As the optimum level
of the cCTG-STV cut-off value was not tested in the
study, the cCTG-STV values adopted as safety-net values
may be used.
How often should we monitor early FGR?
There is no international consensus on the optimal
frequency of monitoring in early FGR. Although the
TRUFFLE protocol specified that DV and CTG should
be monitored at least weekly, most centers (17 of 20)
performed cCTG at least daily. A longitudinal analysis
of these data in women delivered before 32weeks
demonstrated that for each day the median risk for a very
low STV or recurrent decelerations (DV Doppler groups’
safety-net criteria) was 5% (IQR, 4–7%)9. It is suggested
that daily monitoring contributed to the good outcomes
seen in this study; however, the frequency of monitoring
in relation to outcome was not tested in the RCT.
How can I use the TRUFFLE results for counseling?
The two bar charts in Figure 3, taken from the TRUFFLE
report of perinatal morbidity and mortality analyzed
Copyright  2017 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2017; 50: 285–290.
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Figure 3 Outcome for: (a) fetuses (n=502) according to gestational age at inclusion; (b) live births (n= 490) according to gestational age at
delivery. ‘n’ row indicates total number of infants represented in each bar (one case is missing). Severe morbidity is defined as broncho-
pulmonary dysplasia, severe germinal matrix cerebral hemorrhage Grade III or IV, cystic periventricular leukomalacia of more than Grade I,
proven neonatal sepsis or necrotizing enterocolitis. , No severe morbidity; , severe morbidity; , neonatal death; , fetal death.
as a cohort2, may be useful in counseling. They give
the main outcome data, according to gestational age,
for counseling women both at study inclusion and at
delivery. For example, if a woman is diagnosed with
FGR, the bar chart ‘at inclusion’ (Figure 3a) is used. If
her pregnancy proceeds a further few weeks and there is
a plan to deliver, the chart ‘at delivery’ (Figure 3b) can be
used to update the counseling.
How often should we monitor maternal blood pressure?
The TRUFFLE study did not evaluate the optimal
frequency of blood pressure monitoring. However, it
was found that, in 70% of cases of FGR, the mother
developed gestational hypertensive morbidity. It would
therefore seem reasonable to recommend checking blood
pressure and urinary protein:creatinine ratio (or using
dip-stick analysis) at each visit or at least weekly in
asymptomatic women with FGR.
Some pregnancies continued beyond 32weeks – what
happened to them?
They were delivered according to the local protocols. In
general, this meant delivery was undertaken at 32weeks
if the umbilical artery end-diastolic flow was reversed, at
34weeks if it was absent, and beyond 34weeks if the
umbilical artery PI was raised. Delivery for the same
criteria at 30weeks, 32weeks and beyond 32weeks,
respectively, was discretionary.
As the upper gestational age at recruitment to TRUF-
FLE study was 31+ 6weeks, the TRUFFLE study cannot
answer the question as to how best to monitor and when
to deliver these slightly older babies. The TRUFFLE
2 randomized study, currently under development,
will test different triggers for delivery in women with
compromised and/or small babies at 32–37weeks
(www.truffle-study.org).
How should we interpret the primary and secondary
results of the TRUFFLE study?
Overall, when restricted to survivors, the outcome
was significantly better in the late-DV compared with
the CTG-STV group. Secondary analysis, restricted to
surviving infants delivered before 32weeks who were
managed according to the study protocol, showed
no difference in the primary outcome between the
DV Doppler groups. Combining both DV Doppler
groups pre-32weeks showed a significantly better
outcome compared with the CTG-STV group (relative
risk, 0.91 (95% CI, 0.83–1.00); number needed to
treat, 13)7,8.
TRUFFLE data provide evidence that management
of pregnancies in which there is early-onset FGR
in a tertiary-level perinatal center and DV Doppler
measurement in conjunction with cCTG improves
long-term infant outcome; a flowchart explaining the
recommended protocol is shown in Figure 4. DV
measurement is not very time-consuming. Our advice,
therefore, is to include DV Doppler measurement with
cCTG for the monitoring of women with early-onset
FGR. It is unlikely that further randomized data will
become available in the near future.
Copyright  2017 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2017; 50: 285–290.
290 Bilardo et al.
Diagnosis of early-onset FGR
 • Singleton fetus
 • 26–32 weeks
 • No obvious anomaly, congenital
     infection or chromosomal defect
 • AC < 10th percentile
 • Umbilical artery Doppler PI > 95th
     percentile
 • Positive DV
 • cCTG:
-  26 + 0 to 28 + 6 weeks,
   STV ≥ 2.6 ms
-  29 + 0 to 31 + 6 weeks,
   STV ≥ 3 ms
-  No repeated decelerations
Decision for active management?
Yes: initiate fetal and maternal
surveillance
 • Measure umbilical artery PI, DV
     and 1-h recording of cCTG
 • Maternal monitoring for
     pre-eclampsia
No: manage as per
local protocol and
parental wishes
Delivery criteria not met: 
Repeat surveillance at least every
2 days
Delivery criteria met:
Deliver after steroid
administration
Assess for delivery criteria:
Late DV changes
• A-wave at or below baseline
cCTG
• 26 + 0 to 28 + 6 weeks,
   STV < 2.6 ms
• 29 + 0 to 31 + 6 weeks,
   STV < 3 ms
• Spontaneous repeated persistent
   unprovoked decelerations
Umbilical artery Doppler
• ≥ 32 + 0 weeks, reversed
   umbilical artery EDF
  (permitted after 30 weeks)
• ≥ 34 + 0 weeks, absent umbilical
   artery EDF
   (permitted after 32 weeks)
Maternal indications
• Local protocol,  e.g. severe
   pre-eclampsia, HELLP syndrome
Figure 4 Flowchart explaining protocol recommended by
TRUFFLE study for monitoring and management of pregnancies
with an early diagnosis of fetal growth restriction (FGR). AC, abdom-
inal circumference; cCTG, computerized cardiotocography; DV,
ductus venosus; EDF, end-diastolic flow; PI, pulsatility index; STV,
short-term variation.
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